This single paragraph provides significant insight into internal priorities. It confirms that, as of 2025, Health officials were actively developing options to revise statutory price-reduction mechanisms to align them with changes to the NMFG. The nature of these changes, however, remains protected via redactions. The justifications for the redactions provide useful insights.
Reread this document - even its redactions reveal that change might be coming
January 13, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The 'Dispatched' Week in Review' Podcast - 4 September
September 4, 2026 - - Podcast -
A three-pronged expansion of Commonwealth reach in therapeutic-goods regulation
September 4, 2026 - - Latest News -
If the government gives itself more power, don't be surprised when they use it
September 4, 2026 - - Latest News -
Medicines Australia calls for doubling of PBS medicines investment
September 4, 2026 - - Latest News -
Gilead returns to Medicines Australia as industry prepares to make the case for innovation
September 3, 2026 - - Latest News -
Combined monitoring of key indicators as the future of diabetes care
September 3, 2026 - - Latest News -
The live lesson from the UK on who holds the levers and how they use them
September 3, 2026 - - Latest News
